Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. VS
VS logo

VS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Versus Systems Inc (VS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
1.140
1 Day change
-2.16%
52 Week Range
2.830
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Versus Systems Inc (VS) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is poor, with revenue dropping to zero and negative earnings trends. Technical indicators suggest a bearish trend, and there are no positive catalysts or significant trading signals to support a buy decision. Given the lack of positive sentiment or growth potential, this stock is better avoided.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 64.933, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point (1.089) with resistance at 1.173 and 1.225, and support at 1.005 and 0.953. Overall, the technical indicators suggest a bearish trend.

Positive Catalysts

  • NULL identified. No recent news or events to act as positive catalysts.

Neutral/Negative Catalysts

  • The company's financials are deteriorating, with revenue dropping to zero, negative net income, and declining EPS. Technical indicators are bearish, and no significant insider or hedge fund activity suggests confidence in the stock.

Financial Performance

In Q3 2025, revenue dropped to 0 (-100% YoY), net income fell to -537,815 (-4.11% YoY), EPS declined to -0.11 (-50% YoY), and gross margin decreased slightly to 99.25% (-0.75% YoY). Overall, the company's financial performance is poor.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes are available for this stock.

Wall Street analysts forecast VS stock price to rise
Analyst Rating
0
Wall Street analysts forecast VS stock price to rise
Buy
Hold
Sell
0
Current: 1.160
sliders
Low
0
Averages
0
High
0
0
Current: 1.160
sliders
Low
0
Averages
0
High
0
UBS
Mauricio Serna
Buy
maintain
$60 -> $73
AI Analysis
2026-01-08
Reason
UBS
Mauricio Serna
Price Target
$60 -> $73
AI Analysis
2026-01-08
maintain
Buy
Reason
UBS analyst Mauricio Serna raised the firm's price target on Victoria's Secret to $73 from $60 and keeps a Buy rating on the shares. CY26 EPS upside for Softline stocks is expected to be driven by a stronger-than-expected U.S. consumer and an underappreciated "Health & Wellness 2.0" trend, with estimates at least 4% above consensus for 16 names, the analyst tells investors in a research note. Earnings momentum is projected to extend into CY27, with EPS forecasts averaging about 5% above consensus, the firm adds.

People Also Watch